PUMA BIOTECHNOLOGY, INC. (PBYI) intrinsic value & 10-year financials
PUMA BIOTECHNOLOGY, INC. (PBYI) has a Graham intrinsic value of $20.26 per share. At $9.83 on Oct 17, 2026, the stock trades 51% below that value. Over the last 10 fiscal years revenue grew 30.2% a year to $228.4M, with an average return on invested capital of -175.2%.
- Graham intrinsic value
- $20.26
- Share price (Oct 17, 2026)
- $9.83
- Price vs Graham value
- 51% below
- Market cap
- $497.9M
- Revenue (FY2025)
- $228.4M
- Revenue growth (10-yr CAGR)
- 30.2%
- ROIC (10-yr avg)
- -175.2%
- Free cash flow (FY2025)
- $41.7M
PBYI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $228.4M | $31.1M | $0.61 | $41.7M | 16.3% | 29.6% |
| FY2024 | $230.5M | $30.3M | $0.62 | $38.9M | 13.4% | 37.1% |
| FY2023 | $235.6M | $21.6M | $0.45 | $26.9M | 13.9% | 47.4% |
| FY2022 | $228.0M | $2.0K | $0.00 | -$15.8M | 10.4% | 23.0% |
| FY2021 | $253.2M | -$29.1M | -$0.72 | $20.6M | 0.5% | 3.5% |
| FY2020 | $225.1M | -$60.0M | -$1.52 | $727.0K | -13.5% | -59.8% |
| FY2019 | $272.3M | -$75.6M | — | $22.1M | -14.4% | -51.2% |
| FY2018 | $251.0M | -$113.6M | — | -$24.5M | -37.7% | -193.5% |
| FY2017 | $27.7M | -$292.0M | — | -$172.9M | -1056.1% | -1456.1% |
| FY2016 | — | -$276.0M | — | -$146.0M | — | -131.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PUMA BIOTECHNOLOGY, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PUMA BIOTECHNOLOGY, INC. has historically struggled to out-earn its cost of capital, averaging just -11.9% ROIC.
PUMA BIOTECHNOLOGY, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PUMA BIOTECHNOLOGY, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $20.26 per share.